Synergistic Enhancement of Paclitaxel-Induced Inhibition of Cell Growth by Metformin in Melanoma Cells
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Melanoma is one of the most aggressive and treatment-resistant malignancies. Antidiabetic drug metformin has been reported to inhibit cell proliferation and metastasis in many cancers, including melanoma. Metformin suppresses the mammalian target of rapamycin (mTOR) and our previous study showed that it also inhibits the activity of extracellular signal-regulated kinase (ERK). Paclitaxel is currently prescribed for treatment of melanoma. However, paclitaxel induced the activation of ERK/mitogen-activated protein kinase (MAPK) pathway, a cell signaling pathway implicated in cell survival and proliferation. Therefore, we reasoned that combined treatment of paclitaxel with metformin could be more effective in the suppression of cell proliferation than treatment of paclitaxel alone. Here, we investigated the combinatory effect of paclitaxel and metformin on the cell survival in SK-MEL-28 melanoma cell line. Our study shows that the combination of paclitaxel and metformin has synergistic effect on cell survival and suppresses the expression of proteins involved in cancer metastasis. These findings suggest that the combination of paclitaxel and metformin can be a possible therapeutic option for treatment of melanoma.
Abstract
Melanoma is one of the most aggressive and treatment-resistant malignancies. Antidiabetic drug metformin has been reported to inhibit cell proliferation and metastasis in many cancers, including melanoma. Metformin suppresses the mammalian target of rapamycin (mTOR) and our previous study showed that it also inhibits the activity of extracellular signal-regulated kinase (ERK). Paclitaxel is currently prescribed for treatment of melanoma. However, paclitaxel induced the activation of ERK/mitogen-activated protein kinase (MAPK) pathway, a cell signaling pathway implicated in cell survival and proliferation. Therefore, we reasoned that combined treatment of paclitaxel with metformin could be more effective in the suppression of cell proliferation than treatment of paclitaxel alone. Here, we investigated the combinatory effect of paclitaxel and metformin on the cell survival in SK-MEL-28 melanoma cell line. Our study shows that the combination of paclitaxel and metformin has synergistic effect on cell survival and suppresses the expression of proteins involved in cancer metastasis. These findings suggest that the combination of paclitaxel and metformin can be a possible therapeutic option for treatment of melanoma.
참고문헌 (31)
- Aguirre-Ghiso JA, "Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth", Cancer Res, 64, pp.7336~7345 (2004)
- Cerezo M, "Metformin blocks melanoma invasion and metastasis development in AMPK", p53-dependent manner, 2013, pp.12, 1605~1615
- Chou TC, "Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors", Eur J Biochem, 115, pp.207~216 (1981)
- Donadon V, "Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease", Liver Int, 30, pp.750~758 (2010)
- Estrada Y, "Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation", Pigment Cell Melanoma Res, 22, pp.66~76 (2008)
- Ganesh T, "Evaluation of the tubulin-bound paclitaxel conformation: Synthesis, biology, and SAR studies of C-4 to C-3’ bridged paclitaxel analogues", J Med Chem, 50, pp.713~725 (2007)
- Griss T, "Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis", PLOS Biol, 13, pp.e1002309~ (2015)
- Gupta A, "DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma", Ann Oncol, 25, pp.968~974 (2014)
- He Y, "Metformin inhibits the migration and invasion of esophageal squamous cell carcinoma cells by downregulating the protein kinase B signaling pathway", Oncol Lett, 15, pp.2939~2945 (2018)
- Hersh EM, "Phase II clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma", Cancer, 116, pp.155~163 (2010)
- Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
- Joshua AM, "A pilot ’window of opportunity’ neoadjuvant study of metformin in localised prostate cancer", Prostate Cancer Prostatic Dis, 17, pp.252~258 (2014)
- Taewan Kim, "Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells", 발생과 생식, 22(2), pp.133~142 (2018), 한국발생생물학회
- Kong F, "Metformin use improves the survival of diabetic combined small-cell lung cancer patients", Tumor Biol, 36, pp.8101~8106 (2015)
- Kottschade LA, "A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group Study, N057E(1)", Cancer, 117, pp.1704~1710 (2011)
- Koul HK, "Role of p38 MAP kinase signal transduction in solid tumors", Genes Cancer, 4, pp.342~359 (2013)
- 이재련, "Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells", 발생과 생식, 21(2), pp.139~150 (2017), 한국발생생물학회
- Li Q, "Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model", FEBS J, 283, pp.2836~2852 (2016)
- McDaid HM, "Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogenactivated protein kinase inhibition in human cancer cell lines", Mol Pharmacology, 60, pp.290~301 (2001)
- Nazarian R, "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation", Nature, 468, pp.973~977 (2010)
- Niehr F, "Combination therapy with vemurafenib (PLX4032", RG7204) and metformin in melanoma cell lines with distinct driver mutations, 2011, pp.9, 76~88
- Niraula S, "Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study", Breast Cancer Res Treat, 135, pp.821~830 (2012)
- Ranchon F, "New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies", AntiCancer Agents Med Chem, 15, pp.461~467 (2015)
- Schuler KM, "Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer", Cancer Med, 4, pp.161~173 (2015)
- Shaw RJ, "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin", Science, 310, pp.1642~1646 (2005)
- Tseng CH, "Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes", J Am Acad Dermatol, 78, pp.694~700 (2018)
- Vancura A, "Metformin as an anticancer agent", Trends Pharmacol Sci, 39, pp.867~878 (2018)
- Villanueva J, "Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R", PI3K, 2010, pp.18, 683~695
- Volk-Draper L, "Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner", Cancer Res, 74, pp.5421~5434 (2014)
- Vujic I, "Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer", Oncotarget, 6, pp.969~978 (2014)
- Xu R, "Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells", Anticancer Res, 29, pp.261~270 (2009)